Psoriatic Arthritis

Effects of Certolizumab Pegol Exposure on Pregnancy Outcomes in Women With Rheumatic Disease

Effects of Certolizumab Pegol Exposure on Pregnancy Outcomes in Women With Rheumatic Disease

By

Researchers sought to provide information on pregnancy outcomes, including major congenital malformations and other maternal and fetal adverse outcomes, in women treated with certolizumab pegol.

Comparing Burden of Psoriatic Arthritis With Different Definitions of Disease Activity

Comparing Burden of Psoriatic Arthritis With Different Definitions of Disease Activity

By

Researchers aimed to compare the disease burden of patients with psoriatic arthritis with low disease activity according to 2 definitions.

Etanercept Monotherapy vs Combination Therapy Examined in Psoriatic Arthritis

Etanercept Monotherapy vs Combination Therapy Examined in Psoriatic Arthritis

By

Etanercept in combination with a conventional synthetic DMARD did not substantially improve clinical response compared with etanercept monotherapy in patients with psoriatic arthritis.

Biosimilar Etanercept SB4 May Decrease Disease Activity in Inflammatory Rheumatic Disease

Biosimilar Etanercept SB4 May Decrease Disease Activity in Inflammatory Rheumatic Disease

By

Nonmandatory transitioning from originator etanercept to biosimilar etanercept SB4 using a specifically designed communication strategy showed a slightly lower persistence rate and smaller decreases in disease activity.

Apremilast Monotherapy Effective for DMARD-Naive Psoriatic Arthritis

Apremilast Monotherapy Effective for DMARD-Naive Psoriatic Arthritis

By

The PALACE 4 trial found that apremilast monotherapy improved symptoms and was generally well-tolerated in DMARD-naive psoriatic arthritis.

Secukinumab Administered by Autoinjector Safe, Effective in Psoriatic Arthritis

Secukinumab Administered by Autoinjector Safe, Effective in Psoriatic Arthritis

By

Results from the FUTURE 3 study show that administration of secukinumab by autoinjector resulted in sustained improvements at 52 weeks in patients with active psoriatic arthritis.

Secukinumab Improves Symptoms, Inhibits Radiographic Progression in Psoriatic Arthritis

Secukinumab Improves Symptoms, Inhibits Radiographic Progression in Psoriatic Arthritis

By

The results of the FUTURE 5 study show that secukinumab improved signs and symptoms and inhibited radiographic structural progression at 24 weeks in psoriatic arthritis.

TNF Inhibitors Reduce Long-Term Disease Activity in Ankylosing Spondylitis, Psoriatic Arthritis

TNF Inhibitors Reduce Long-Term Disease Activity in Ankylosing Spondylitis, Psoriatic Arthritis

By

TNFi therapy yielded favorable results in patients with AS or PsA, with progressively better responses between 4 months and 3 years.

Dual Neutralization of IL-17A, IL-17F With Bimekizumab Suppresses PsA Joint Inflammation

Dual Neutralization of IL-17A, IL-17F With Bimekizumab Suppresses PsA Joint Inflammation

By

Dual inhibition of IL-17A and IL-17F with bimekizumab suppresses joint inflammation in patients with psoriatic arthritis.

Thickened Pulleys in PsA Support Deep Koebnerization in Dactylitis

Thickened Pulleys in PsA Support Deep Koebnerization in Dactylitis

By

The accessory pulleys linked to the flexor tendons are thicker in patients with psoriatic arthritis.

FDA Label Update for Certolizumab Pegol Affects Women of Childbearing Age

FDA Label Update for Certolizumab Pegol Affects Women of Childbearing Age

By

The FDA has approved a label update to include pharmacokinetic data showing low transfer of certolizumab pegol through placenta and minimal transfer to breast milk from mother to infant.

Early Response in Psoriatic Arthritis Treatment Predicts Long-Term Outcomes

Early Response in Psoriatic Arthritis Treatment Predicts Long-Term Outcomes

By

Initial response to psoriatic arthritis therapy has a predictive value of long-term outcomes as early as 3 months after treatment initiation.

Patients With PsA Achieve Early, Sustained Minimal Disease Activity With Secukinumab

Patients With PsA Achieve Early, Sustained Minimal Disease Activity With Secukinumab

By

Results from the FUTURE 2 study show that patients with PsA who were treated with secukinumab achieved early and sustained minimal disease activity over 2 years of therapy.

High Coronary Plaque Burden Is Independent of Metabolic Syndrome in Psoriatic Arthritis

High Coronary Plaque Burden Is Independent of Metabolic Syndrome in Psoriatic Arthritis

By

Psoriatic arthritis is associated with accelerated coronary plaque formation, particularly mixed plaques, independent of metabolic disease.

Increased HLA-B27 Associated With More Severe Sonographic Enthesitis in PsA

Increased HLA-B27 Associated With More Severe Sonographic Enthesitis in PsA

By

In patients with psoriatic arthritis, increasing levels of HLA-B27 are associated with more severe sonographic enthesitis.

Spondyloarthritis Increases Risk for Dysrhythmias and Aortic Regurgitation

Spondyloarthritis Increases Risk for Dysrhythmias and Aortic Regurgitation

By

The risk for aortic regurgitation and cardiac rhythm abnormalities was evaluated in a nationwide cohort of patients with spondyloarthritis.

Efficacy and Safety of Ixekizumab Evaluated in Active Psoriatic Arthritis

Efficacy and Safety of Ixekizumab Evaluated in Active Psoriatic Arthritis

By

Results from the phase 3 SPIRIT-P1 study show that treatment with ixekizumab every 2 or 4 weeks in patients with active psoriatic arthritis demonstrated sustained efficacy and a favorable safety profile.

Efficacy of Apremilast Monotherapy Assessed in Biologic-Naive Psoriatic Arthritis

Efficacy of Apremilast Monotherapy Assessed in Biologic-Naive Psoriatic Arthritis

By

Patients with psoriatic arthritis who are taking apremilast experienced early symptom relief and sustained clinical improvement through 1 year of treatment.

Hyperuricemia in Psoriatic Arthritis: Identifying Features to Improve Outcomes

Hyperuricemia in Psoriatic Arthritis: Identifying Features to Improve Outcomes

By

A cohort study was conducted to determine the long-term outcomes especially of cardiovascular and kidney diseases in patients with psoriatic arthritis with comorbid hyperuricemia.

Risk of Liver Disease Increased With Psoriatic Arthritis

Risk of Liver Disease Increased With Psoriatic Arthritis

By

There is a higher risk for liver disease in patients with inflammatory disorders.

JAK Inhibitors Now Approved For Treatment of Active Psoriatic Arthritis

JAK Inhibitors Now Approved For Treatment of Active Psoriatic Arthritis

By

The FDA has approved tofacitinib and tofacitinib extended release to treat active psoriatic arthritis.

Updating Treatment Strategies for PsA: Aiming for Minimal Disease Activity

Updating Treatment Strategies for PsA: Aiming for Minimal Disease Activity

By

Rapid expansion of effective therapies for psoriatic arthritis has driven new, ambitious treatment targets of minimal disease activity and disease remission.

Overlap Between Remission and Low Disease Activity Targets in Psoriatic Arthritis

Overlap Between Remission and Low Disease Activity Targets in Psoriatic Arthritis

By

Investigators compared composite scores defining low disease activity state or remission in an existing real-life data set of patients with PsA.

Examining the Implications of Accelerated Coronary Plaque Formation in Psoriatic Arthritis

Examining the Implications of Accelerated Coronary Plaque Formation in Psoriatic Arthritis

By

Disease severity and activity in psoriatic arthritis may predict coronary plaque burden better than traditional risk factors.

Characterization of Rheumatic Disorders Associated With Immune Checkpoint Inhibitor Use

Characterization of Rheumatic Disorders Associated With Immune Checkpoint Inhibitor Use

By

A prospective, observational study sought to evaluate and characterize the nature of rheumatic disorders associated with immune checkpoint inhibitors.

CV Risk Scores Underestimate Subclinical Atherosclerosis in Psoriatic Arthritis

CV Risk Scores Underestimate Subclinical Atherosclerosis in Psoriatic Arthritis

By

Cardiovascular risk assessment tools in patients with PsA have been shown to underestimate the risk for carotid subclinical atherosclerosis.

Examining Smoking Paradox in PsA Development for Patients With Psoriasis

Examining Smoking Paradox in PsA Development for Patients With Psoriasis

By

Smoking is positively associated with the risk for PsA in the general population, but negatively associated with PsA in patients with psoriasis.

Psoriatic Arthritis Questionnaire Reliable, Feasible in Clinical Practice

Psoriatic Arthritis Questionnaire Reliable, Feasible in Clinical Practice

By

The Psoriatic Arthritis Impact of Disease Questionnaire is a reliable patient-reported outcome measure with utility among patients with psoriatic arthritis in clinical practice.

FDA Approves Ixekizumab for Treatment of Active Psoriatic Arthritis in Adults

FDA Approves Ixekizumab for Treatment of Active Psoriatic Arthritis in Adults

By

The FDA has approved ixekizumab for the treatment of adults with psoriatic arthritis.

Discontinuation of Biosimilar Infliximab Associated With Subjective Complaints

Discontinuation of Biosimilar Infliximab Associated With Subjective Complaints

By

Transitioning from an originator agent to its biosimilar has the potential to reduce healthcare costs without compromising outcomes.

Sign Up for Free e-newsletters